ID: ALA1201770
Chembl Id: CHEMBL1201770
Cas Number: 73232-52-7
PubChem CID: 5361917
Product Number: N133576
Max Phase: Approved
First Approval: 2008
Molecular Formula: C21H26BrNO4
Molecular Weight: 356.44
Molecule Type: Small molecule
Associated Items:
Synonyms: Show More⌵
Trade Names(1): Relistor
Canonical SMILES: C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
Standard InChI: InChI=1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1
Standard InChI Key: IFGIYSGOEZJNBE-KNLJMPJLSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: Yes | Chemical Probe: No | Parenteral: Yes |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: Yes | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 356.44 | Molecular Weight (Monoisotopic): 356.1856 | AlogP: 1.67 | #Rotatable Bonds: 2 |
| Polar Surface Area: 66.76 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 9.90 | CX Basic pKa: | CX LogP: -2.49 | CX LogD: -2.34 |
| Aromatic Rings: 1 | Heavy Atoms: 26 | QED Weighted: 0.79 | Np Likeness Score: 1.89 |
| 1. Unpublished dataset, |
| 2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 3. WHO Anatomical Therapeutic Chemical Classification, |
| 4. British National Formulary (72nd edition), |
| 5. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 6. Unpublished dataset, |
| 7. Inagaki M, Kume M, Tamura Y, Hara S, Goto Y, Haga N, Hasegawa T, Nakamura T, Koike K, Oonishi S, Kanemasa T, Kai H.. (2019) Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects., 29 (1): [PMID:30446313] [10.1016/j.bmcl.2018.11.007] |
| 8. Long DD, Armstrong SR, Beattie DT, Campbell CB, Church TJ, Colson PJ, Dalziel SM, Jacobsen JR, Jiang L, Obedencio GP, Rapta M, Saito D, Stergiades I, Tsuruda PR, Van Dyke PM, Vickery RG.. (2019) Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist., 10 (12): [PMID:31857840] [10.1021/acsmedchemlett.9b00406] |
| 9. European Medicines Agency, |
Source(7):
